Format

Send to

Choose Destination
Quintessence Int. 2016 Apr;47(4):319-27. doi: 10.3290/j.qi.a34974.

Topical sulfasalazine for unresponsive oral lichen planus.

Abstract

OBJECTIVE:

The purpose of this study was to evaluate the usefulness of topical sulfasalazine in the treatment of oral lichen planus (OLP) resistant to corticosteroid therapy.

METHOD AND MATERIALS:

Twenty-one unresponsive OLP patients were treated with topical sulfasalazine 3 times a day for 4 weeks. Each patient's symptoms and lesion size were evaluated at the beginning of therapy, and then after 4 weeks to determine the efficacy of topical sulfasalazine. Inflammatory cytokines levels in saliva were measured by ELISA.

RESULTS:

Seventeen patients (81%) reported improvement of discomfort and 12 patients (57%) had lesions decrease in size over 50%. Patients who had higher levels of IL-1β and IL-8 were more responsive to topical sulfasalazine therapy.

CONCLUSION:

Topical sulfasalazine should be considered when OLP does not respond to corticosteroid therapy. Furthermore, high concentrations of IL-1β and IL-8 in the saliva are useful indicators for the application of topical sulfasalazine in OLP patients refractory to steroid treatment.

PMID:
26504904
DOI:
10.3290/j.qi.a34974
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Quintessence Publishing Co., Ltd
Loading ...
Support Center